DocWire News Editors

DocwireNews

Biosimilars are increasing in popularity, notably in the oncology world. Therefore, for this study, researchers evaluated oncology clinicians&rsquo; current understanding and knowledge of biosimilars, and what education gaps should be addressed in order to adopt biosimilars.A total of 77 oncology clinicians (52 physicians, 16 pharmacists, and nine advanced practice practitioners) completed a three-pronged survey pertaining to clinician understanding, prescription preferences, and patient involvement. Results from the first 50 surveys guided researchers to create an in-depth interview regarding cost, safety and efficacy, patient preference, and disease stage. The interview participants were selected based on outlying survey responses.One of the survey questions required an open-ended response to define &ldquo;biosimilar,&rdquo; which was given a score from 0 to 4. Respondents received one point each if they mentioned four predetermined components: a biosimilar is biologic, is manufactured differently from the reference product, has similar efficacy and safety, and has the same mechanism of action. A score of 2 or above was considered satisfactory, while a 1 or 0 was considered unsatisfactory. About three-quarters (74 percent, n = 57/77) of participants were not able to give a satisfactory definition for &ldquo;biosimilar&rdquo;; 40.3 percent (n = 31/77) equated a biosimilar to a generic drug.Researchers gave respondents a composite understanding score based on their answers to the first five survey questions, which included the open-ended biosimilar definition question. The remaining questions were:<ul>
<li>Please rate your overall familiarity with developments in biosimilars in oncology (extremely familiar, moderately familiar, somewhat familiar, slightly familiar, not at all familiar)</li>
<li>A biosimilar agent has the same chemical structure and manufacturing process as the reference brand name agent (true/false)</li>
<li>Biosimilars are currently approved for the treatment of which of the following cancers? (bone, pancreatic, lung, kidney, colorectal, liver)*</li>
<li>What must a biosimilar demonstrate in order to be given the designation of being interchangeable by the US FDA? (it must have the same amino acid sequence as reference drug, it can be alternated with reference product with no change in safety or efficacy, the cost must be similar to the reference drug, it is given the designation by the US FDA when approved as a biosimilar) 
*Per the researchers: &ldquo;For question 4, naming one or two of the cancers for which a biosimilar is approved was scored as partially correct, naming all three was scored as correct and naming a cancer with no approved biosimilar resulted in an incorrect score&rdquo;</li>
</ul>The mean composite understanding score for all respondents was 2.02; scores ranged from 0.05 to 3.50.When asked what factors were most important to consider when prescribing a biosimilar, the top-rated answers were safety and efficacy (4.51 out of 5) and cost differences (4.34 out of 5). Clinicians were 40 percent more likely to prescribe a biosimilar if it had interchangeable status (53.2 percent versus 94.8 percent). About half (50.7 percent, n = 39/77) of respondents said shared decision-making with patients is important or extremely important, while 39 percent (n = 30/77) said it is somewhat or not at all important. Respondents were torn on the importance of disclosing to patients that they were being prescribed a biosimilar (important or extremely important, 46.8 percent [n = 36/77] versus somewhat or not at all important, 42.9 percent [n = 33/77]).Based on the results, the researchers concluded that there is a significant need for biosimilar education for oncology clinicians. Information regarding safety, efficacy, and cost must be provided before clinicians can prescribe biosimilars to their patients.Read more at Therapeutic Advances in Medical Oncology (<a href="https://journals.sagepub.com/doi/10.1177/1758835918818335">https://journals.sagepub.com/doi/10.1177/1758835918818335</a>)

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Academic Oncology Clinicians’ Understanding of Biosimilars and Information Needed Before Prescribing

Oncology

Biosimilars are increasing in popularity, notably in the oncology world. Therefore, for this study, researchers evaluated oncology clinicians’ current understanding and ...

Academic Oncology Clinicians’ Understanding of Biosimilars and Information Needed Before

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe